[go: up one dir, main page]

BR0311898A - Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3 - Google Patents

Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3

Info

Publication number
BR0311898A
BR0311898A BR0311898-3A BR0311898A BR0311898A BR 0311898 A BR0311898 A BR 0311898A BR 0311898 A BR0311898 A BR 0311898A BR 0311898 A BR0311898 A BR 0311898A
Authority
BR
Brazil
Prior art keywords
anxiety
depression
antagonists
combination treatment
antagonist
Prior art date
Application number
BR0311898-3A
Other languages
English (en)
Inventor
Susan Beth Sobolov-Jaynes
John Adams Lowe Iii
Stafford Mclean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0311898A publication Critical patent/BR0311898A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TRATAMENTO DE ASSOCIAçãO PARA DEPRESSãO E ANSIEDADE COM ANTAGONISTAS DE NK1 E NK3". A presente invenção relaciona-se com um método para o tratamento da depressão ou ansiedade num mamífero, incluindo um ser humano, pela administração ao mamífero de um antagonista do receptor de NK-1 penetrante no SNC (e.g., um antagonista do receptor de substância P) em associação com um agente antagonista de NK-3. Relaciona-se também com composições farmacêuticas contendo um veículo farmaceuticamente aceitável, um antagonista do receptor de NK-1 penetrante no SNC e um antagonista de NK-3.
BR0311898-3A 2002-06-19 2003-06-10 Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3 BR0311898A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38997502P 2002-06-19 2002-06-19
PCT/IB2003/002516 WO2004000355A1 (en) 2002-06-19 2003-06-10 Combination treatment for depression and anxiety by nk1 and nk3 antagonists

Publications (1)

Publication Number Publication Date
BR0311898A true BR0311898A (pt) 2005-04-12

Family

ID=30000494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311898-3A BR0311898A (pt) 2002-06-19 2003-06-10 Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3

Country Status (8)

Country Link
US (1) US20040006135A1 (pt)
EP (1) EP1517708A1 (pt)
JP (1) JP2005533080A (pt)
AU (1) AU2003239280A1 (pt)
BR (1) BR0311898A (pt)
CA (1) CA2488311A1 (pt)
MX (1) MXPA05000260A (pt)
WO (1) WO2004000355A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005015158A2 (en) 2003-08-06 2005-02-17 Senomyx Inc. T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
SG159528A1 (en) 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
PL1928454T3 (pl) 2005-05-10 2015-03-31 Intermune Inc Pochodne pirydonu do modulowania układu kinazy białkowej aktywowanego stresem
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
TWI674069B (zh) 2006-04-21 2019-10-11 美商賽諾米克斯公司 包含高度鮮味風味劑之可食用組合物及其製造方法
JP4799434B2 (ja) * 2007-01-31 2011-10-26 イスクラ産業株式会社 向精神剤
WO2009026408A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
BR112015026519A2 (pt) 2013-04-19 2017-07-25 Astrazeneca Ab composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
ES2842592T3 (es) * 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
CN110105279B (zh) * 2019-04-15 2022-09-16 中山大学 一种喹啉类stat3特异性抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929303B1 (en) * 1996-10-07 2006-07-26 Merck Sharp & Dohme Ltd. Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
NZ521346A (en) * 2000-04-10 2004-07-30 Pfizer Prod Inc Benzoamide piperidine containing compounds and related compounds
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist

Also Published As

Publication number Publication date
EP1517708A1 (en) 2005-03-30
US20040006135A1 (en) 2004-01-08
AU2003239280A1 (en) 2004-01-06
CA2488311A1 (en) 2003-12-31
WO2004000355A1 (en) 2003-12-31
MXPA05000260A (es) 2005-04-11
JP2005533080A (ja) 2005-11-04

Similar Documents

Publication Publication Date Title
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
HUP0301920A2 (hu) P anyag receptor antagonista és magnézium vegyület kombinációját tartalmazó agy-, gerinc- és idegsérülés kezelésére szolgáló injekciós készítmény
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
IL159527A0 (en) Human dr4 antibodies and uses thereof
IL162616A (en) Benzooxazine, benzothiazine and quinoline analogues as cholinergic receptor agonists and use thereof in the preparation of medicaments for treating diseases
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
ATE355288T1 (de) Verbindungen und therapeutische methoden
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma
GB9805559D0 (en) A combination of therapeutic agents
AU7476501A (en) New use of angiotensin ii antagonists
EP2266558A3 (en) Treatment of neuropathic pain with N-methyl-D-aspartate (NMDA) receptor antagonists
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
EP1260221A3 (en) Combination treatment for depression and anxiety

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 DA RPI 2116 DE 26/07/2011.